Xcellerex, Inc. announced today that it has received the Invensys Operations Management OPEN award. Xcellerex is one of four companies recognized by Invensys Operations Management, a global provider of technology systems, software solutions and consulting services. Contestants were recognized for their innovative use of Invensys products and solutions to generate significant business results in four Operational Excellence categories.
Xcellerex was awarded for Productivity Excellence. Using several Invensys® solutions, including Wonderware System Platform, InBatch™, InTouch HMI, Historian Software and Historian Client products, the Xcellerex technology platform allows manufacturing capacity to be deployed rapidly, flexibly and at significantly reduced cost compared with conventional technology.
“Xcellerex has embraced the groundbreaking capabilities inherent within the Wonderware System Platform and InBatch products, leveraging that power to augment the value delivered to their customers,” said Darren Kline, director, marketing and Business Development, Wonderware North. “We are proud that this partnership has helped Xcellerex uniquely blend the benefits of Wonderware software along with their own advanced technology to redefine
Ken Clapp, Xcellerex Senior Director of Marketing & Product Management, commented, “Our automation team does a tremendous job integrating complex bioprocess operations in our facility and for our clients. Our bioprocess automation simplifies life for our clients, and also gives them greater control and peace-of-mind in running their operations. To be recognized by an industry leader like Invensys is a great honor for us.”
David Mills, Xcellerex Senior Director of MES & Automation, accepted the award for Xcellerex during the Invensys OpsManage'10 global conference series, which was held recently in Orlando, Florida.
Xcellerex’s FlexFactory is an innovative, portable biomanufacturing platform, based on the innovative application of (1) single-use technologies; (2) controlled environmental modules (CEMs); and (3) advanced and proven process automation including electronic batch records. The FlexFactory effectively eliminates clean- and steam-in-place requirements and clean room infrastructure; greatly simplifies facility design, reducing manufacturing footprint and capital investment; and creates breakthrough gains in operating efficiency, flexibility and environmental friendliness.
About Xcellerex, Inc.
Xcellerex is commercializing turnkey biomanufacturing solutions that transform the speed and economics of producing therapeutic proteins, including biosimilars and vaccines. The company’s FlexFactory® is a complete modular and portable production train based on single-use technologies, advanced process automation, and compact clean room architecture.
FlexFactory allows deployment of GMP manufacturing capacity more rapidly and at greatly reduced costs compared with traditional facilities. Through its BridgeSourcing™ services, Xcellerex manufactures a partner’s biomolecules while the partner prepares for commissioning of its own new FlexFactory. When the partner’s facility is ready, Xcellerex deploys its TransPlant™ process to install, validate and train partner personnel in their own FlexFactory. This parallel-path model both accelerates time to clinical and commercial manufacturing and allows partners to manage the development and market risks associated with adding manufacturing capacity.
Xcellerex also leverages its proprietary single use technologies through the sale of XDR bioreactors, XDM Quad Mixers, and related single-use assemblies. To date, more than 20 therapeutic proteins and vaccines have been manufactured for clinical trials using Xcellerex technology.
Based in Marlborough, Massachusetts, Xcellerex is backed by an experienced management team and top-tier venture investors including Kleiner Perkins Caufield & Byers, VantagePoint Venture Partners and SCG Capital. For more information, please visit the company’s website at http://www.xcellerex.com.